Cellectar Biosciences Inc News - CLRBW

Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

FLORHAM PARK, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage...

Cellectar Biosciences to Present at the Biotech Showcase

FLORHAM PARK, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a...

Cellectar Granted Japanese Patent for CLR 131

FLORHAM PARK, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a...

Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

FLORHAM PARK, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage...

Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

FLORHAM PARK, N.J., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB...

Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

Clinical Trials to Advance Across Multiple Hematology Programs FLORHAM PARK, N.J., Nov. 12, 2018 (GLOBE...

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myelo...

MADISON, Wis., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage...

Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

MADISON, Wis., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a...

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

MADISON, Wis., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a...

Cellectar Biosciences Provides an Update on the FDA Import Alert

MADISON, Wis., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a...

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

MADISON, Wis., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a...

Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

MADISON, Wis., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a...

Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients

Positive Results from Cohort 5 of Phase 1b TrialCompany Intends to Initiate a Sixth Cohort and Transition...

Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma

MADISON, Wis., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage...

Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update

MADISON, Wis., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB)(“Cellectar or “the...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cellectar Biosciences Inc (CLRBW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CLRBW News

Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

Cellectar Biosciences to Present at the Biotech Showcase

Cellectar Granted Japanese Patent for CLR 131

Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myelo...

Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

Cellectar Biosciences Provides an Update on the FDA Import Alert

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients

Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma

Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update

CLRBW Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cellectar Biosciences Inc (CLRBW) News

Cellectar Biosciences Inc (CLRBW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CLRBW News

Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

Cellectar Biosciences to Present at the Biotech Showcase

Cellectar Granted Japanese Patent for CLR 131

Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myelo...

Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

Cellectar Biosciences Provides an Update on the FDA Import Alert

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients

Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma

Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update

CLRBW Discussion

Your Recent History